ClinVar Miner

Submissions for variant NM_001256317.3(TMPRSS3):c.326G>A (p.Arg109Gln)

gnomAD frequency: 0.00009  dbSNP: rs139484231
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 5
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Eurofins Ntd Llc (ga) RCV000493533 SCV000231181 uncertain significance not provided 2014-12-10 criteria provided, single submitter clinical testing
GeneDx RCV000493533 SCV000582645 likely pathogenic not provided 2017-05-18 criteria provided, single submitter clinical testing The R109Q variant in the TMPRSS3 gene has been reported previously in the compound heterozygous state in an individual with moderate non-syndromic hearing loss (Gu et al., 2015). The R109Q variant is a semi-conservative amino acid substitution, which may impact secondary protein structure as these residues differ in some properties. This substitution occurs at a position that is conserved across species. In silico analysis is inconsistent in its predictions as to whether or not the variant is damaging to the protein structure/function. A different missense variant at this residue (R109W) has been reported in the Human Gene Mutation Database in association with non-syndromic hearing loss (Stenson et al., 2014), supporting the functional importance of this region of the protein. The R109Q variant is not observed at a significant frequency in large population cohorts (Lek et al., 2016; 1000 Genomes Consortium et al., 2015; Exome Variant Server). We interpret R109Q as a likely pathogenic variant.
Illumina Laboratory Services, Illumina RCV001140696 SCV001300979 uncertain significance Autosomal recessive nonsyndromic hearing loss 8 2017-04-27 criteria provided, single submitter clinical testing This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). No publications were found based on this search. Allele frequency data from public databases did not allow this variant to be ruled in or out of causing disease. Therefore, this variant is classified as a variant of unknown significance.
Invitae RCV000493533 SCV002232524 pathogenic not provided 2024-01-29 criteria provided, single submitter clinical testing This sequence change replaces arginine, which is basic and polar, with glutamine, which is neutral and polar, at codon 109 of the TMPRSS3 protein (p.Arg109Gln). This variant is present in population databases (rs139484231, gnomAD 0.03%). This missense change has been observed in individual(s) with sensorineural deafness (PMID: 24853665; Invitae). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 197857). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt TMPRSS3 protein function with a positive predictive value of 80%. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. This variant disrupts the p.Arg109 amino acid residue in TMPRSS3. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 11424922, 12920079, 28566687). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic.
PreventionGenetics, part of Exact Sciences RCV003416097 SCV004117363 uncertain significance TMPRSS3-related disorder 2023-02-16 criteria provided, single submitter clinical testing The TMPRSS3 c.326G>A variant is predicted to result in the amino acid substitution p.Arg109Gln. This variant was reported in the compound heterozygous state in a patient with non-syndromic hearing loss (Gu et al 2015. PubMed ID: 24853665). This variant is reported in 0.037% of alleles in individuals of Latino descent in gnomAD ( Although we suspect that this variant may be pathogenic, at this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.